AMBEV S.A. (ABEV) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 29, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F for FY2025, filed Mar 3, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ABEV SEC filings page.
AMBEV S.A. (ABEV) reported $16.1B in revenue for fiscal year 2025, up 11.4% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of AMBEV S.A.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
AMBEV S.A. has an operating margin of 26.4%, meaning the company retains $26 of operating profit per $100 of revenue. This strong profitability earns a score of 90/100, reflecting efficient cost management and pricing power. This is up from 24.4% the prior year.
AMBEV S.A.'s revenue grew 11.4% year-over-year to $16.1B, a solid pace of expansion. This earns a growth score of 28/100.
AMBEV S.A. carries a low D/E ratio of 0.03, meaning only $0.03 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 94/100, indicating a strong balance sheet with room for future borrowing.
AMBEV S.A.'s current ratio of 0.96 is below the typical benchmark, resulting in a score of 18/100. This tight liquidity could limit financial flexibility if cash inflows slow.
AMBEV S.A. converts 22.5% of revenue into free cash flow ($3.6B). This strong cash generation earns a score of 89/100.
AMBEV S.A. earns a strong 17.6% return on equity (ROE), meaning it generates $18 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 90/100. This is up from 14.6% the prior year.
AMBEV S.A. passes 6 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
For every $1 of reported earnings, AMBEV S.A. generates $1.58 in operating cash flow ($4.5B OCF vs $2.8B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
AMBEV S.A. earns $5.29 in operating income for every $1 of interest expense ($4.3B vs $805.3M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
AMBEV S.A. generated $16.1B in revenue in fiscal year 2025. This represents an increase of 11.4% from the prior year.
AMBEV S.A.'s EBITDA was $5.5B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 17.7% from the prior year.
AMBEV S.A. reported $2.8B in net income in fiscal year 2025. This represents an increase of 21.2% from the prior year.
AMBEV S.A. earned $0.18 per diluted share (EPS) in fiscal year 2025. This represents an increase of 22.3% from the prior year.
Cash & Balance Sheet
AMBEV S.A. generated $3.6B in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 5.0% from the prior year.
AMBEV S.A. held $3.4B in cash against $405.3M in long-term debt as of fiscal year 2025, with $8.3B of liabilities due within a year.
Not reported for fiscal year 2025.
Margins & Returns
AMBEV S.A.'s gross margin was 51.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 0.2 percentage points from the prior year.
AMBEV S.A.'s operating margin was 26.4% in fiscal year 2025, reflecting core business profitability. This is up 2.0 percentage points from the prior year.
AMBEV S.A.'s net profit margin was 17.6% in fiscal year 2025, showing the share of revenue converted to profit. This is up 1.4 percentage points from the prior year.
AMBEV S.A.'s ROE was 17.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 3.0 percentage points from the prior year.
Capital Allocation
AMBEV S.A. invested $838.1M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 9.1% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
ABEV Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F | FY1520-F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $16.1B+11.4% | $14.5B-12.0% | $16.4B+9.0% | $15.1B+15.4% | $13.1B+16.3% | $11.2B-13.1% | $12.9B0.0% | $12.9B-10.5% | $14.5B+3.2% | $14.0B+18.8% | $11.8B |
| Cost of Revenue | $7.8B+11.0% | $7.1B-12.9% | $8.1B+5.9% | $7.6B+19.6% | $6.4B+22.7% | $5.2B-3.4% | $5.4B+8.7% | $5.0B-8.9% | $5.4B+6.2% | $5.1B+26.4% | $4.1B |
| Gross Profit | $8.3B+11.8% | $7.4B-11.1% | $8.3B+12.2% | $7.4B+11.4% | $6.7B+10.7% | $6.0B-20.1% | $7.5B-5.5% | $8.0B-11.5% | $9.0B+1.4% | $8.9B+14.8% | $7.7B |
| Operating Income | $4.3B+20.8% | $3.5B-9.2% | $3.9B+16.0% | $3.3B+9.2% | $3.1B-0.4% | $3.1B-23.1% | $4.0B-9.5% | $4.4B-11.6% | $5.0B-5.0% | $5.3B+10.9% | $4.7B |
| EBITDA | $5.5B+17.7% | $4.7B-10.1% | $5.2B+16.3% | $4.5B+10.9% | $4.0B-0.9% | $4.1B-21.2% | $5.2B-7.2% | $5.6B-10.5% | $6.2B-1.9% | $6.3B+14.8% | $5.5B |
| Interest Expense | $805.3M+23.6% | $651.4M+30.0% | $501.3M+13.8% | $440.5M+71.5% | $256.8M-25.3% | $344.0M-8.7% | $376.8M-1.7% | $383.5M-29.1% | $540.9M+13.7% | $475.6M+77.2% | $268.4M |
| Income Tax | $626.9M-16.5% | $750.4Mn/m | -$15.6M-112.5% | $124.0Mn/m | -$114.2M-133.6% | $339.4M+80.7% | $187.8M-58.9% | $457.1M-70.0% | $1.5B+1473.9% | $96.8M-89.5% | $917.9M |
| Net Income | $2.8B+21.2% | $2.3B-21.9% | $3.0B+9.3% | $2.7B+20.3% | $2.3B+3.7% | $2.2B-25.2% | $2.9B+3.4% | $2.8B+29.1% | $2.2B-43.1% | $3.9B+22.9% | $3.1B |
| EPS (Basic) | $0.18+22.1% | $0.15-21.8% | $0.19+9.3% | $0.17+20.3% | $0.14+3.7% | $0.14-25.3% | $0.19+3.4% | $0.18+29.1% | $0.14-43.1% | $0.25+23.2% | $0.20 |
| EPS (Diluted) | $0.18+22.3% | $0.15-21.8% | $0.19+9.3% | $0.17+20.4% | $0.14+3.8% | $0.14-25.2% | $0.18+3.4% | $0.18+28.9% | $0.14-43.1% | $0.24+22.2% | $0.20 |
| Diluted Shares (Avg) | 15.68B-0.8% | 15.81B-0.2% | 15.84B-0.1% | 15.85B-0.1% | 15.86B-0.1% | 15.87B0.0% | 15.87B+0.1% | 15.86B+0.1% | 15.84B+0.1% | 15.82B0.0% | 15.82B |
Not reported in any period shown, so not listed: R&D Expenses, SG&A Expenses.
ABEV Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F | FY1520-F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $26.5B+0.8% | $26.3B-3.9% | $27.3B+4.7% | $26.1B+5.0% | $24.9B+3.1% | $24.1B-4.8% | $25.3B+2.6% | $24.7B-8.0% | $26.8B+4.0% | $25.8B+13.2% | $22.8B |
| Current Assets | $8.0B-8.5% | $8.8B+16.2% | $7.5B+5.3% | $7.2B+3.3% | $6.9B+1.8% | $6.8B-1.0% | $6.9B+5.3% | $6.5B-12.5% | $7.5B+1.6% | $7.3B | N/A |
| Cash & Equivalents | $3.4B-26.4% | $4.6B+39.7% | $3.3B+17.2% | $2.8B-5.3% | $3.0B-9.4% | $3.3B+11.1% | $3.0B+0.2% | $3.0B-5.5% | $3.1B+29.1% | $2.4B | N/A |
| Inventory | $1.9B+1.6% | $1.9B-4.6% | $2.0B-18.9% | $2.4B+23.9% | $2.0B+34.7% | $1.5B-1.6% | $1.5B+6.9% | $1.4B+6.8% | $1.3B-2.4% | $1.3B | N/A |
| Accounts Receivable | $1.2B+14.4% | $1.0B-14.3% | $1.2B+16.9% | $1.0B+17.7% | $859.5M+3.7% | $828.6M-25.9% | $1.1B-11.0% | $1.3B-15.8% | $1.5B+11.2% | $1.3B | N/A |
| Goodwill | $7.6B+5.8% | $7.2B-8.5% | $7.8B+2.0% | $7.7B+0.9% | $7.6B-1.3% | $7.7B-11.5% | $8.7B-1.4% | $8.8B-6.8% | $9.5B+1.1% | $9.4B+20.0% | $7.8B |
| Total Liabilities | $10.3B+1.0% | $10.2B-6.0% | $10.8B+4.7% | $10.3B+5.6% | $9.8B+1.6% | $9.6B-1.2% | $9.8B-1.1% | $9.9B-16.0% | $11.7B+2.7% | $11.4B+13.6% | $10.1B |
| Current Liabilities | $8.3B+4.2% | $8.0B-5.5% | $8.5B+10.2% | $7.7B+10.0% | $7.0B+8.2% | $6.4B+3.6% | $6.2B-4.2% | $6.5B-25.0% | $8.7B-2.1% | $8.8B | N/A |
| Non-Current Liabilities | $2.0B-10.7% | $2.2B-7.6% | $2.4B-11.1% | $2.7B-5.5% | $2.8B-11.6% | $3.2B-9.6% | $3.5B+4.9% | $3.4B+9.4% | $3.1B+18.8% | $2.6B | N/A |
| Long-Term Debt | $405.3M+15.2% | $351.9M-22.5% | $454.0M-94.3% | $8.0B+7.8% | $7.4B+11.6% | $6.6B-4.9% | $7.0B+1150.2% | $557.3M+49.8% | $371.9M-31.5% | $542.8M | N/A |
| Total Equity | $16.1B+0.6% | $16.0B-2.0% | $16.3B+5.0% | $15.5B+4.6% | $14.8B+4.3% | $14.2B-6.8% | $15.2B+5.2% | $14.5B+4.4% | $13.9B+0.8% | $13.8B+8.4% | $12.7B |
| Retained Earnings | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -$107.3M | N/A | N/A |
Not reported in any period shown, so not listed: Short-Term Investments, Long-Term Investments.
ABEV Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F | FY1520-F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $4.5B+5.8% | $4.2B-17.1% | $5.1B+30.4% | $3.9B-4.9% | $4.1B+13.1% | $3.6B-20.6% | $4.6B-3.3% | $4.7B-14.2% | $5.5B+45.3% | $3.8B-36.3% | $6.0B |
| Depreciation & Amortization | $1.2B+8.2% | $1.2B-12.9% | $1.3B+17.4% | $1.1B+16.4% | $968.0M-2.7% | $995.0M-14.5% | $1.2B+1.5% | $1.1B-5.9% | $1.2B+12.9% | $1.1B+39.0% | $776.6M |
| Capital Expenditures | $838.1M+9.1% | $768.0M-37.9% | $1.2B+0.1% | $1.2B-10.3% | $1.4B+52.4% | $903.6M-28.4% | $1.3B+37.1% | $920.3M-4.9% | $967.3M-22.0% | $1.2B-8.7% | $1.4B |
| Free Cash Flow | $3.6B+5.0% | $3.5B-10.5% | $3.9B+44.4% | $2.7B-2.3% | $2.7B+0.1% | $2.7B-17.7% | $3.3B-13.0% | $3.8B-16.2% | $4.5B+78.0% | $2.6B-44.4% | $4.6B |
| Investing Cash Flow | -$903.8Mn/m | -$883.5Mn/m | -$1.2Bn/m | -$946.7Mn/m | -$1.4Bn/m | -$1.3Bn/m | -$1.2Bn/m | -$947.2Mn/m | -$927.8Mn/m | -$1.8Bn/m | -$1.5B |
| Financing Cash Flow | -$4.9Bn/m | -$1.7Bn/m | -$3.3Bn/m | -$3.1Bn/m | -$2.9Bn/m | -$1.7Bn/m | -$3.1Bn/m | -$3.5Bn/m | -$4.0Bn/m | -$3.6Bn/m | -$3.9B |
Not reported in any period shown, so not listed: Stock-Based Compensation, Dividends Paid, Share Buybacks.
ABEV Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F | FY1520-F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 51.4%+0.2pp | 51.2%+0.5pp | 50.7%+1.4pp | 49.3%-1.8pp | 51.0%-2.6pp | 53.6%-4.7pp | 58.3%-3.4pp | 61.7%-0.7pp | 62.4%-1.1pp | 63.4%-2.2pp | 65.6% |
| Operating Margin | 26.4%+2.0pp | 24.4%+0.8pp | 23.6%+1.4pp | 22.2%-1.3pp | 23.4%-3.9pp | 27.4%-3.5pp | 30.9%-3.2pp | 34.1%-0.4pp | 34.6%-2.9pp | 37.5%-2.7pp | 40.2% |
| Net Margin | 17.6%+1.4pp | 16.1%-2.1pp | 18.2%+0.1pp | 18.1%+0.8pp | 17.4%-2.1pp | 19.5%-3.2pp | 22.7%+0.8pp | 21.9%+6.7pp | 15.2%-12.3pp | 27.5%+0.9pp | 26.6% |
| Return on Equity | 17.6%+3.0pp | 14.6%-3.7pp | 18.4%+0.7pp | 17.6%+2.3pp | 15.3%-0.1pp | 15.4%-3.8pp | 19.2%-0.3pp | 19.6%+3.8pp | 15.8%-12.2pp | 28.0%+3.3pp | 24.7% |
| Return on Assets | 10.7%+1.8pp | 8.9%-2.0pp | 10.9%+0.4pp | 10.5%+1.3pp | 9.1%+0.1pp | 9.1%-2.5pp | 11.6%+0.1pp | 11.5%+3.3pp | 8.2%-6.8pp | 15.0%+1.2pp | 13.8% |
| Current Ratio | 0.96-0.1x | 1.10+0.2x | 0.890.0x | 0.93-0.1x | 0.99-0.1x | 1.060.0x | 1.10+0.1x | 1.00+0.1x | 0.860.0x | 0.83 | N/A |
| Debt-to-Equity | 0.030.0x | 0.020.0x | 0.03-0.5x | 0.510.0x | 0.500.0x | 0.470.0x | 0.46+0.4x | 0.040.0x | 0.030.0x | 0.04 | N/A |
| Liabilities-to-Equity | 0.640.0x | 0.640.0x | 0.660.0x | 0.670.0x | 0.660.0x | 0.680.0x | 0.640.0x | 0.68-0.2x | 0.840.0x | 0.830.0x | 0.79 |
| Asset Turnover | 0.61+0.1x | 0.55-0.1x | 0.600.0x | 0.58+0.1x | 0.53+0.1x | 0.470.0x | 0.510.0x | 0.520.0x | 0.540.0x | 0.540.0x | 0.52 |
| FCF Margin | 22.5%-1.4pp | 23.9%+0.4pp | 23.5%+5.8pp | 17.7%-3.2pp | 20.9%-3.4pp | 24.3%-1.3pp | 25.6%-3.8pp | 29.4%-2.0pp | 31.4%+13.2pp | 18.2%-20.7pp | 39.0% |
Note: The current ratio is below 1.0 (0.96), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| AMBEV S.A. ABEV | FY2025 | $16.1B | $2.8B | 17.6% | $41.2B | 68/100 |
| FOMENTO ECONOMICO MEXICANO, S.A.B. DE C.V. FMX | FY2025 | $46.7B | $1.8B | 3.9% | $42.3B | 63/100 |
| Constellation Brands, Inc. STZ | FY2026 | $9.1B | $1.7B | 18.5% | $22.1B | 48/100 |
| Anheuser-Busch InBev SA/NV BUD | FY2025 | $59.3B | $6.8B | 11.5% | $156.6B | 51/100 |
| Molson Coors Beverage Company TAP | FY2025 | $13.0B | -$2.1B | -16.4% | $7.3B | 32/100 |
| Boston Beer Company SAM | FY2025 | $2.0B | $108.5M | 5.5% | $2.0B | 54/100 |
Where AMBEV S.A. Ranks
Frequently Asked Questions
What is AMBEV S.A.'s annual revenue?
AMBEV S.A. (ABEV) reported $16.1B in total revenue for fiscal year 2025. This represents a 11.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is AMBEV S.A.'s revenue growing?
AMBEV S.A. (ABEV) revenue grew by 11.4% year-over-year, from $14.5B to $16.1B in fiscal year 2025.
Is AMBEV S.A. profitable?
Yes, AMBEV S.A. (ABEV) reported a net income of $2.8B in fiscal year 2025, with a net profit margin of 17.6%.
What is AMBEV S.A.'s EBITDA?
AMBEV S.A. (ABEV) had EBITDA of $5.5B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does AMBEV S.A. have?
As of fiscal year 2025, AMBEV S.A. (ABEV) had $3.4B in cash and equivalents against $405.3M in long-term debt.
What is AMBEV S.A.'s gross margin?
AMBEV S.A. (ABEV) had a gross margin of 51.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is AMBEV S.A.'s operating margin?
AMBEV S.A. (ABEV) had an operating margin of 26.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is AMBEV S.A.'s net profit margin?
AMBEV S.A. (ABEV) had a net profit margin of 17.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is AMBEV S.A.'s return on equity (ROE)?
AMBEV S.A. (ABEV) has a return on equity of 17.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is AMBEV S.A.'s free cash flow?
AMBEV S.A. (ABEV) generated $3.6B in free cash flow during fiscal year 2025. This represents a 5.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is AMBEV S.A.'s operating cash flow?
AMBEV S.A. (ABEV) generated $4.5B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are AMBEV S.A.'s total assets?
AMBEV S.A. (ABEV) had $26.5B in total assets as of fiscal year 2025, including both current and long-term assets.
What are AMBEV S.A.'s capital expenditures?
AMBEV S.A. (ABEV) invested $838.1M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is AMBEV S.A.'s current ratio?
AMBEV S.A. (ABEV) had a current ratio of 0.96 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is AMBEV S.A.'s debt-to-equity ratio?
AMBEV S.A. (ABEV) had a debt-to-equity ratio of 0.03 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
What is AMBEV S.A.'s liabilities-to-equity ratio?
AMBEV S.A. (ABEV) had a liabilities-to-equity ratio of 0.64 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
What is AMBEV S.A.'s return on assets (ROA)?
AMBEV S.A. (ABEV) had a return on assets of 10.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is AMBEV S.A.'s P/E ratio?
AMBEV S.A. (ABEV) trades at 14.5x earnings, its market capitalization divided by $2.8B net income, FY2025. The market capitalization is $41.2B as of Oct 29, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is AMBEV S.A.'s price-to-sales ratio?
AMBEV S.A. (ABEV) trades at 2.6x sales, its market capitalization divided by $16.1B revenue, FY2025. The market capitalization is $41.2B as of Oct 29, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is AMBEV S.A.'s Piotroski F-Score?
AMBEV S.A. (ABEV) has a Piotroski F-Score of 6 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are AMBEV S.A.'s earnings high quality?
AMBEV S.A. (ABEV) has an earnings quality ratio of 1.58x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can AMBEV S.A. cover its interest payments?
AMBEV S.A. (ABEV) has an interest coverage ratio of 5.29x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is AMBEV S.A.?
AMBEV S.A. (ABEV) scores 68 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.